Akeso's ivonescimab secures NMPA Priority Review status for first-line biliary tract cancer treatment, marking a potential regulatory milestone for the company's lead asset in China.
China's NMPA granted Priority Review to ivonescimab plus chemotherapy for first-line locally advanced or metastatic biliary tract cancer, announced 4 Nov 2026. A priority review shortens the regulatory path toward a new label expansion for Akeso's lead drug, which supports the shares. The article gives no approval date, market size or financial terms, and priority review does not guarantee approval, which caps the reaction.
Priority Review for ivonescimab combined with chemotherapy as a first-line treatment for locally advanced or metastatic biliary tract cancer.
No. The announcement only says the submission received Priority Review from the NMPA; approval has not been granted.
Akeso, Inc. announced that China's National Medical Products Administration (NMPA) has granted Priority Review to its lead drug, ivonescimab. The therapy, used in combination with chemotherapy, is being evaluated as a first-line treatment for locally advanced or metastatic biliary tract cancer.
Priority Review for ivonescimab combined with chemotherapy as a first-line treatment for locally advanced or metastatic biliary tract cancer.
No. The announcement only says the submission received Priority Review from the NMPA; approval has not been granted.